The Global Regenerative Medicine Partnering 2010-2016: Deal
trends, players, financials and forecasts report provides comprehensive
understanding and unprecedented access to the regenerative medicine including
cell therapy, organ regeneration, stem cells and tissue regeneration partnering
deals and agreements entered into by the worlds leading healthcare companies
Description
The Global Regenerative Medicine Partnering 2010-2016: Deal
trends, players, financials and forecasts report provides comprehensive
understanding and unprecedented access to the regenerative medicine including
cell therapy, organ regeneration, stem cells and tissue regeneration partnering
deals and agreements entered into by the worlds leading healthcare companies.
- Trends in regenerative medicine
- Deal terms analysis
- Partnering agreement structure
- Partnering contract documents
- Top deals by value
- Most active dealmakers
- Average deal terms for regenerative medicine and stem cells
The report provides a detailed understanding and analysis of
how and why companies enter Regenerative Medicine partnering deals. These deals
tend to be multicomponent, starting with collaborative R&D, and proceed to
commercialization of outcomes.
This report provides details of the latest Regenerative
Medicine agreements announced in the life sciences since 2010.
The report takes the reader through a comprehensive review
Regenerative Medicine deal trends, key players, top deal values, as well as
deal financials, allowing the understanding of how, why and under what terms,
companies are entering Regenerative Medicine partnering deals.
The report presents financial deal term values for
Regenerative Medicine deals, listing by headline value, upfront payments,
milestone payments and royalties, enabling readers to analyse and benchmark the
financial value of deals.
The middle section of the report explores the leading
dealmakers in the Regenerative Medicine partnering field; both the leading deal
values and most active Regenerative Medicine dealmaker companies are reported
allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 950
online deal records of actual Regenerative Medicine deals, as disclosed by the
deal parties, are included towards the end of the report in a directory format
– by company A-Z, stage of development, deal type, therapy focus, and
technology type - that is easy to reference. Each deal record in the report
links via Weblink to an online version of the deal.
In addition, where available, records include contract
documents as submitted to the Securities Exchange Commission by companies and
their partners. Whilst many companies will be seeking details of the payment
clauses, the devil is in the detail in terms of how payments are triggered –
contract documents provide this insight where press releases and databases do
not.
The initial chapters of this report provide an orientation
of Regenerative Medicine dealmaking. Chapter 1 provides an introduction to the
report, whilst chapter 2 provides an overview of the trends in Regenerative
Medicine dealmaking since 2010, including details of headline, upfront,
milestone and royalty terms.
Chapter 3 provides a review of the leading Regenerative
Medicine deals since 2010. Deals are listed by headline value. Where the deal
has an agreement contract published at the SEC a link provides online access to
the contract.
Chapter 4 provides a comprehensive listing of the top 25
most active companies in Regenerative Medicine dealmaking with a brief summary
followed by a comprehensive listing of Regenerative Medicine deals announded by
that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of
Regenerative Medicine partnering deals signed and announced since Jan 2010,
where a contract document is available in the public domain. Each deal title
links via Weblink to an online version of the deal record and contract
document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of
Regenerative Medicine partnering deals signed and announced since Jan 2010. The
chapter is organized by specific Regenerative Medicine technology type. Each
deal title links via Weblink to an online version of the deal record and where
available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized
by Regenerative Medicine partnering company A-Z, stage of development, deal
type, and therapy focus. Each deal title links via Weblink to an online version
of the deal record and where available, the contract document, providing easy
access to each deal on demand.
The report also includes numerous tables and figures that
illustrate the trends and activities in Regenerative Medicine partnering and
dealmaking since 2010.
In conclusion, this report provides everything a prospective
dealmaker needs to know about partnering in the research, development and
commercialization of Regenerative Medicine technologies and products.
Key benefits
Global Regenerative Medicine Partnering 2010-2016: Deal
trends, players, financials and forecasts provides the reader with the
following key benefits:
- In-depth understanding of Regenerative Medicine deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of Regenerative Medicine agreements with numerous real life case studies
- Detailed access to actual Regenerative Medicine contracts entered into by leading biopharma companies
- Identify most active Regenerative Medicine dealmakers since 2010
- Insight into terms included in a Regenerative Medicine partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Global Regenerative Medicine Partnering 2010-2016: Deal
trends, players, financials and forecasts is intended to provide the reader
with an in-depth understanding and access to Regenerative Medicine trends and
structure of deals entered into by leading companies worldwide.
Regenerative Medicine Partnering Terms and Agreements
includes:
- Trends in Regenerative Medicine dealmaking in the biopharma industry since 2010
- Analysis of Regenerative Medicine deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life Regenerative Medicine deals
- Access to Regenerative Medicine contract documents
- Leading Regenerative Medicine deals by value since 2010
- Most active Regenerative Medicine dealmakers since 2010
In Global Regenerative Medicine Partnering 2010-2016:
Deal trends, players, financials and forecasts, the available deals are listed
by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type
The Global Regenerative Medicine Partnering 2010-2016: Deal
trends, players, financials and forecasts report provides comprehensive access
to available deals and contract documents for over 950 Regenerative Medicine
deals.
Analyzing actual contract agreements allows assessment of
the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Benefits
Global Regenerative Medicine Partnering 2010-2016: Deal
trends, players, financials and forecasts provides the reader with the following
key benefits:
- In-depth understanding of Regenerative Medicine deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of Regenerative Medicine agreements with numerous real life case studies
- Detailed access to actual Regenerative Medicine contracts entered into by leading biopharma companies
- Identify most active Regenerative Medicine dealmakers since 2010
- Insight into terms included in a Regenerative Medicine partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Spanning over 660 pages “Global Regenerative
Medicine Partnering 2010-2016: Deal trends, players, financials and forecasts” report covers Executive
Summary, Introduction, Trends in Regenerative Medicine dealmaking, Leading
Regenerative Medicine deals, Most active Regenerative Medicine dealmakers,
Regenerative Medicine contracts dealmaking directory, Regenerative Medicine
dealmaking by technology type, Partnering resource center, Appendices.
For
more information Visit at: http://mrr.cm/33S
Related Reports;
Global Pharmacogenomics Partnering Terms and Agreements 2010
to 2016 - Visit at - http://mrr.cm/33T
Global Joint Venture Partnering Terms and Agreements in
Pharma, Biotech and Diagnostics 2010-2016 - Visit at - http://mrr.cm/33q
Global Dermatology Partnering 2010-2016: Deal trends,
players and financials - Visit at - http://mrr.cm/33c
Global Gastrointestinal Partnering 2010-2016: Deal trends,
players and financials - Visit at - http://mrr.cm/33p
No comments:
Post a Comment
Note: only a member of this blog may post a comment.